Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Feb. 25, 2022 | Jun. 30, 2021 | |
Document and Entity Information | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Transition Report | false | ||
Entity File Number | 001-32295 | ||
Entity Registrant Name | FENNEC PHARMACEUTICALS INC. | ||
Entity Incorporation, State or Country Code | CA | ||
Entity Tax Identification Number | 20-0442384 | ||
Entity Address, Address Line One | PO Box 13628, 68 TW Alexander Drive | ||
Entity Address, City or Town | Research Triangle Park | ||
Entity Address, State or Province | NC | ||
Entity Address, Postal Zip Code | 27709 | ||
City Area Code | 919 | ||
Local Phone Number | 636-4530 | ||
Title of 12(b) Security | Common Shares, no par value | ||
Trading Symbol | FENCF | ||
Security Exchange Name | NASDAQ | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Common Stock, Shares Outstanding | 26,013,519 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0001211583 | ||
Amendment Flag | false | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Public Float | $ 97,834,286 | ||
ICFR Auditor Attestation Flag | false | ||
Auditor Name | Haskell & White LLP | ||
Auditor Firm ID | 200 | ||
Auditor Location | Irvine, California |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets | ||
Cash and cash equivalents | $ 21,100 | $ 30,344 |
Prepaid expenses | 1,034 | 797 |
Other current assets | 253 | 276 |
Total current assets | 22,387 | 31,417 |
Non-current assets | ||
Deferred issuance cost, net amortization | 27 | |
Total non-current assets | 27 | |
Total assets | 22,414 | 31,417 |
Current liabilities: | ||
Accounts payable | 777 | 1,571 |
Accrued liabilities | 877 | 776 |
Total current liabilities | 1,654 | 2,347 |
Long term liabilities | ||
Term loan | 5,000 | |
Debt discount | (12) | |
Total long term liabilities | 4,988 | |
Total liabilities | 6,642 | 2,347 |
Commitments and Contingencies (Note 7) | ||
Shareholders' equity: | ||
Common stock, no par value; unlimited shares authorized; 26,014 shares issued and outstanding (2020 26,003) | 140,801 | 140,733 |
Additional paid-in capital | 53,214 | 49,234 |
Accumulated deficit | (179,486) | (162,140) |
Accumulated other comprehensive income | 1,243 | 1,243 |
Total shareholders' equity | 15,772 | 29,070 |
Total liabilities and shareholders' equity | $ 22,414 | $ 31,417 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Consolidated Balance Sheets | ||
Common stock, no par value | $ 0 | $ 0 |
Common stock, shares issued | 26,014 | 26,003 |
Common stock, shares outstanding | 26,014 | 26,003 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Consolidated Statements of Operations | ||
Revenue | $ 170 | |
Operating expenses: | ||
Research and development | $ 4,981 | 5,105 |
General and administrative | 12,242 | 12,950 |
Total operating expenses | 17,223 | 18,055 |
Loss from operations | (17,223) | (17,885) |
Other (expense)/income | ||
Unrealized foreign exchange loss | (10) | |
Amortization expense | (16) | (402) |
Unrealized (loss)/gain on securities | (25) | 100 |
Interest income | 54 | 87 |
Interest expense | (126) | (9) |
Total other (expense)/income | (123) | (224) |
Net loss | $ (17,346) | $ (18,109) |
Basic net loss per common share | $ (0.67) | $ (0.76) |
Diluted net loss per common share | $ (0.67) | $ (0.76) |
Weighted-average number of common shares outstanding basic | 26,006 | 23,704 |
Weighted-average number of common shares outstanding diluted | 26,006 | 23,704 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Operating activities: | ||
Net loss | $ (17,346) | $ (18,109) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Amortization of debt access fees | 14 | 402 |
Amortization of debt discount | 2 | |
Unrealized loss on securities | 25 | (100) |
Stock-based compensation - consultants | 266 | 84 |
Stock-based compensation - employees | 3,749 | 2,791 |
Changes in operating assets and liabilities: | ||
Prepaid expenses | (237) | (163) |
Other assets | (2) | (168) |
Accounts payable | (794) | (41) |
Accrued liabilities | 101 | (291) |
Net cash used in operating activities | (14,222) | (15,595) |
Financing activities: | ||
Issuance of shares, options exercise | 33 | 462 |
Issuance of shares, net of issuance costs | 31,967 | |
Proceeds from long-term debt | 5,000 | |
Debt discount | (14) | |
Capitalized deferred issuance costs | (41) | (140) |
Net cash provided by financing activities | 4,978 | 32,289 |
(Decrease)/increase in cash and cash equivalents | (9,244) | 16,694 |
Cash and cash equivalents - Beginning of period | 30,344 | 13,650 |
Cash and cash equivalents - End of period | 21,100 | 30,344 |
Non-cash investing and financing activities: | ||
Financed insurance policy | $ 466 | $ 408 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Common StockEmployees | Common StockConsultants | Common Stock | Additional Paid-in CapitalEmployees | Additional Paid-in CapitalConsultants | Additional Paid-in Capital | Accumulated DeficitEmployees | Accumulated DeficitConsultants | Accumulated Deficit | Accumulated Other Comprehensive IncomeEmployees | Accumulated Other Comprehensive IncomeConsultants | Accumulated Other Comprehensive Income | Employees | Consultants | Total |
Balance at Dec. 31, 2019 | $ 106,392 | $ 48,271 | $ (144,031) | $ 1,243 | $ 11,875 | ||||||||||
Balance (in shares) at Dec. 31, 2019 | 19,896 | ||||||||||||||
Stock options issued | $ 0 | $ 0 | $ 2,791 | $ 84 | $ 0 | $ 0 | $ 0 | $ 0 | $ 2,791 | $ 84 | |||||
Issuance of securities | $ 31,967 | 0 | 0 | 0 | 31,967 | ||||||||||
Issuance of securities (in shares) | 5,460 | ||||||||||||||
Exercise of stock options | $ 2,374 | (1,912) | 0 | 0 | 462 | ||||||||||
Exercise of stock options (in shares) | 647 | ||||||||||||||
Net loss | $ 0 | 0 | (18,109) | 0 | (18,109) | ||||||||||
Balance at Dec. 31, 2020 | $ 140,733 | 49,234 | (162,140) | 1,243 | 29,070 | ||||||||||
Balance (in shares) at Dec. 31, 2020 | 26,003 | ||||||||||||||
Stock options issued | $ 0 | $ 0 | $ 3,749 | $ 266 | $ 0 | $ 0 | $ 0 | $ 0 | $ 3,749 | $ 266 | |||||
Exercise of stock options | $ 68 | (35) | 0 | 0 | 33 | ||||||||||
Exercise of stock options (in shares) | 11 | ||||||||||||||
Net loss | $ 0 | 0 | (17,346) | 0 | (17,346) | ||||||||||
Balance at Dec. 31, 2021 | $ 140,801 | $ 53,214 | $ (179,486) | $ 1,243 | $ 15,772 | ||||||||||
Balance (in shares) at Dec. 31, 2021 | 26,014 |
Nature of Business and Liquidit
Nature of Business and Liquidity | 12 Months Ended |
Dec. 31, 2021 | |
Nature of Business and Liquidity | |
Nature of Business and Liquidity | 1. Nature of Business and Liquidity Fennec Pharmaceuticals Inc. (“Fennec,” “the Company,” “we,” “us,” or “our”) was originally formed as a British Columbia corporation under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), collectively referred to herein as the “Company,” is a biopharmaceutical company with a product candidate under development for use in the treatment of cancer. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive. These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the year ended December 31, 2021, the Company incurred a loss from operations of $17,223 and still has not earned any significant revenue in its history from the commercial sale of its product candidate. At December 31, 2021, it had an accumulated deficit of $179,486 and had experienced negative cash flows from operating activities in the amount of $14,222 for the year ended December 31, 2021. On May 5, 2020, the Company announced the completion of an underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share. In addition, Fennec issued an additional 660,204 common shares in connection with the partial exercise of the underwriters' over-allotment option. The approximate total gross proceeds from the offering was $34,100 ($32,189 net of commissions, fees and issue costs). On February 1, 2019, Fennec entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, an Arizona corporation, pursuant to which the Bank agreed to loan $12.5 million to the Company, to be made available upon New Drug Application ("NDA") approval of PEDMARKTM by no later than September 30, 2020. Interest under the Term Loans shall bear interest, on the outstanding daily balance thereof, at a floating per annum rate equal to the Effective Interest Rate (as defined in the Loan and Security Agreement) which is equal to the sum of the Prime Rate published in the Wall Street Journal (currently 3.25%) plus one percent (1.00%). The debt facility was to have interest-only monthly payments due for the first eighteen months from the funding date and then monthly principal and interest payments are due through the remainder of the term which had a maturity date of October 1, 2023. In connection with the facility, Fennec granted Bridge Bank a warrant to purchase up to 39,130 common shares at an exercise price of $6.80 per common share, for a term of ten years from the date of issuance, subject to early termination under certain conditions. On June 25, 2020, Fennec entered into an amendment to the Loan and Security Agreement with Bridge Bank. This amendment provided Fennec with an $18.0 million debt facility comprised of two term loans. Term Loan A consisted of $12.5 million to be funded upon NDA approval of PEDMARK TM by no later than December 31, 2020 and Term Loan B consists of $5.5 million to be funded upon the occurrence of a revenue event in 2021. The interest-only period for the facility had the ability to be extended from 18 months to 24 months from the funding of Term Loan A, provided that Term Loan B is funded, and certain conditions are met. The fee in connection with Loan B, would either be 2.13% of the Loan B amount in cash, or the Company could issue a warrant with a value equal to 3.25% of the Loan B amount. On August 6, 2020, the Company paid cash for the extended facility. These statements reflect that fee being settled with cash instead of a warrant. Under Accounting Standards Codification ("ASC") 470-50, Modifications and Extinguishments, the amendment was considered a modification. As such, the Company had been amortizing the loan fee and the value of the warrant over the remainder of the loan term. Following the receipt of the U.S. Food and Drug Administration's ("FDA") Complete Response Letter ("CRL"), management decided to fully amortize the remaining portions of the loan fee and the value of the warrants. On June 24, 2021, the Company entered into a second amendment to the Bridge Bank Loan and Security Agreement. This amendment provides Fennec with a $20,000 debt facility comprised of three term loans. Term Loan A consists of TM not later than January 31, 2022. Term Loan C consists of from the funding of Term Loan B, provided that Term Loan C is funded, and certain other conditions are met. On January 27, 2022, the Company entered into a third amendment to the Bridge Bank Loan and Security Agreement extending the outside date to receive NDA approval of PEDMARK TM 30, 2022 constitutes an event of default under the Bridge Bank Loan and Security Agreement, upon which Bridge Bank may declare the entire balance of the facility immediately due and payable. Although Bridge Bank has previously extended the deadline to receive NDA approval, there is no assurance that it will do so again if the NDA is not approved by the current September 30, 2022 deadline. The proceeds from the loan will to be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. On August 10, 2020, the Company received a CRL from the FDA regarding its NDA for PEDMARK TM TM On November 29, 2021, the Company received a second CRL from the FDA regarding its NDA for PEDMARK TM The Company believes the funds raised in its May 2020 public offering, along with the funds from the Bridge Bank Loan and Security Agreement, provide sufficient funding for the Company to carry out its planned activities, including, if PEDMARK TM TM These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate. |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies | |
Significant Accounting Policies | 2. Significant Accounting Policies Basis of presentation The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of stock-based compensation. Actual results could differ from those estimates. Cash and Cash Equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2021, the Company had $21.1 million in cash and money market accounts (2020- $30.3 million). Money market investments typically have minimal risks. While the Company has not experienced any loss or write-down of its money market investments, the amounts it holds in money market accounts are substantially above the $250,000 amount insured by the FDIC and may lose value. Financial instruments Financial instruments recognized on the balance sheets at December 31, 2021 and December 31, 2020 consist of cash and cash equivalents, accounts payable, accrued liabilities and long term debt, the carrying values of which, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trading or speculative nature. Common shares and warrants The Company has 0.04 million warrants with a weighted average strike price of $6.80 outstanding to purchase common shares that were denominated in United States dollars (“USD”). Revenue The Company's revenue is generated through sales of intellectual property ("IP"). For periods when the Company has generated revenue, the revenue recognized under each of the Company’s arrangements during those periods is described below. The terms of these agreements may contain multiple promised goods or services or optional goods and services, including licenses to product candidates, referred to as exclusive licenses, as well as research and development activities to be performed by the Company on behalf of the collaboration partner related to the licensed product candidates. Revenue recognition Revenue is recognized when control of the promised goods or services are transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or providing services. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods or services, the Company considers the point at which the customer may benefit from the goods or services. For sale of IP, revenue is recognized upon grant or transfer of the IP, as the Company's IP is considered functional in nature. Performance obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may contain multiple performance obligations if a promise to transfer goods or services is separately identifiable from other promises in a contract and, therefore, is considered distinct. For contracts with multiple performance obligations, the Company determines the standalone selling price of each performance obligation and allocates the total transaction price using the relative selling price basis. The Company recognizes performance obligations based on their nature. Significant payment terms The Company's revenue arrangements include payments to the Company of one or more of the following: a non-refundable, upfront payment; milestone payments and royalties on commercial sales of IP product candidates, if any. To date, the Company has received upfront payments and several milestone payments but has not received any license or option fees or earned royalty revenue as a result of product sales. Under ASC 606, the Company estimates the amount of consideration to which it will be entitled in exchange for satisfying performance obligations. Based on the Company's current contracts, variable consideration primarily exists in the following forms: development and regulatory milestones, royalties and sales-based milestones. The Company utilizes the "most likely amount" variable consideration method for estimating development and regulatory milestone consideration to include in the transaction price. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company refers to this as the variable consideration constraint. Due to the uncertainty associated with the occurrence of the underlying events which would trigger development and regulatory milestone consideration under its revenue arrangements, with the exception of certain initial conditions precedent milestones, the Company has concluded the variable consideration associated with all development and regulatory milestones to be fully constrained as of the ASC 606 transition date and as of December 31, 2021, and therefore has not included such consideration in the transaction price for any of its revenue arrangements. The Company will reassess this conclusion at each subsequent reporting period and will only include amounts associated with regulatory or development milestones in the transaction price when, or if, the variable consideration is determined to be released from the constraint. In accordance with ASC 606, the Company is required to adjust the transaction price for the effects of the time value of money if the timing of payments agreed to by the parties to the contract, explicitly or implicitly, provides the Company or its customer with a significant benefit of financing the transfer of goods or services. The Company concluded that its licensing and collaboration arrangements do not contain a significant financing component because the payment structure of its agreements arise from reasons other than providing a significant benefit of financing. Contract assets The Company did not have a contract asset as of December 31, 2021 or 2020. Contract liabilities The Company did not have a contract liability as of December 31, 2021 or 2020. Revenue arrangements Elion In May 2016, Fennec sold its rights to the drug Eniluracil to Elion Oncology, LLC (“Elion”). The agreement called for $40,000 in cash and 5% royalties to be paid to Fennec for any income derived from the sale of Eniluracil. The agreement was for the sale, not license of Fennec’s rights in Eniluracil. In addition, the agreement did not call for any additional good or service beyond the transfer of Fennec’s rights in Eniluracil and related assets (e.g. "all information and know-how", documentation, etc.). In August 2020, Elion entered into a license agreement with Processa Pharmaceuticals, Inc. (“Processa”) for Eniluracil. The license agreement called for equity and cash upon satisfying the "Condition Precedent", along with development and regulatory milestone payments, Sales Milestone Payments, and Product Royalties. The grant of the license was conditioned upon the "Condition Precedent" which was defined as (i) Processa's closing of a public offering by October 30, 2020 in which Processa raised at least $15 million and (ii) Processa's shares being listed on NASDAQ. Upon satisfying the "Condition Precedent" Elion was entitled to receive $100,000 in cash and 825,000 in shares of Processa of which the Company is entitled to 5%. In January 2021, the Company received $5,000 in cash and 41,250 restricted shares of Processa common shares. The agreement between Elion and Processa entitles Elion to the payments outlined in the table below. Fennec would be eligible to receive 5% of the following based on future milestone events: Milestone Event Milestone Payment ($) 1st Year Anniversary of Effective Date 100 Restricted Shares 2nd Year Anniversary of Effective Date 100 Restricted Shares 1st Patient in Dose Confirmation Study 100 Restricted Shares NDA Submission 300 Restricted Shares 1st FDA Approval in US $ 5,000 2nd FDA Approval in US $ 3,000 1st Regulatory Approval Outside US $ 2,000 2nd Regulatory Approval Outside US $ 2,000 The Company notes that the above payments are conditioned upon the “Condition Precedent” and thus even the restricted shares that are due only upon the passage of time are in fact variable. However, once the “Condition Precedent” occurred only the passage of time must occur in order for the 1 st nd st nd th The arrangement with Elion contains consideration that is variable based on the customer’s achievement of certain development and regulatory milestones. The next milestone payment the Company may be entitled to receive is 5,000 restricted shares for 1 st The Company recognized $0.2 million in revenue associated with the aforementioned cash and shares it became entitled to for the year ended December 31, 2020. Due to the one year lockup provision on the Processa shares, the Company deemed it reasonable to apply a liquidity discount of 20% to the valuation of the shares associated with the achievement of the October 30, 2020 milestone. Shares associated with the one- and two-year anniversary milestones had a 30 and 40% liquidity discount applied to their fair market valuations. Recognizing the passage of time, the Company adjusted its liquidity discount to the original shares of Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the consolidated statement of operations. During the year ended December 31, 2021, the Company reported $25 in unrealized loss on the fair value of the underlying Processa shares. There is a total unrealized gain on the Processa shares of $75 since inception. Research and development costs and investment tax credits Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred. Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made, and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized. Income taxes The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December 31, 2021, we maintained a full valuation allowance against our deferred tax assets. The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. Foreign currency translation The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations. Loss per share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number of common shares outstanding includes convertible debentures, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, warrants to purchase 0.04 million of our common shares and options to purchase 4.3 million of our common shares at December 31, 2021, were not included in earnings per share. Such options would have an antidilutive effect. In 2020, warrants to purchase 0.04 million of our common shares and options to purchase 3.0 million common shares were excluded from the computation of earnings per share as their inclusion would have been antidilutive. Recent accounting pronouncements In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848). In this ASU, the FASB refines the scope of Topic 848 to clarify that certain optional expedients and exceptions therein for contract modifications and hedge accounting apply to contracts that are affected by the discounting transition. Specifically, modifications related to reference rate reform would not be considered an event that requires reassessment of previous accounting conclusions. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The amendments in the ASU are effective immediately for all entities. Entities may choose to apply the amendments retrospectively as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively to new modifications from any date within an interim period that includes or is subsequent to January 7, 2021, up to the date that financial statements are available to be issued. The Company chose to apply amendments prospectively and concluded after evaluation that ASU 2021-01 has no significant effect on our consolidated financial statements. |
Loss per Share
Loss per Share | 12 Months Ended |
Dec. 31, 2021 | |
Loss per Share | |
Loss per Share | 3. Loss per Share Loss per common share is presented under two formats: basic loss per common share and diluted loss per common share. Basic loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common shares equivalents (e.g. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data): Year Ended December 31, 2021 December 31, 2020 Numerator: Net loss $ (17,346) $ (18,109) Denominator: Weighted-average common shares, basic 26,006 23,704 Dilutive effect of stock options — — Dilutive effect of warrants — — Incremental dilutive shares — — Weighted-average common shares, diluted 26,006 23,704 Net loss per share, basic and diluted $ (0.67) $ (0.76) The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Year Ended December 31, 2021 December 31, 2020 Options to purchase common shares 4,259 2,952 Warrants to purchase common shares 39 39 |
Stock options
Stock options | 12 Months Ended |
Dec. 31, 2021 | |
Stock options | |
Stock options | 4. Stock options The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of common shares issuable under the stock option plan from a fixed number of 6.7 million to the number of shares that represents twenty-five percent (25%) of the total number of all issued and outstanding common shares. Based upon the current shares outstanding, a maximum of 6.5 million of our common shares are authorized for issuance under the plan. The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of ten years from the date of grant. The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, for the years ended December 31, 2021 and 2020 is below. Summary of $CAD Option Activity Number of Weighted Share Prices Reported in $CAD Options Range Average (in thousands) Outstanding and exercisable at December 31, 2019 648 $ 2.43 $ 2.43 Exercised (648) 2.43 2.43 Outstanding and exercisable at December 31, 2020 — $ — $ — Outstanding and exercisable at December 31, 2021 — $ — $ — Summary of $USD Option Activity Number of Options Weighted (in thousands) Range Average Outstanding and exercisable at December 31, 2019 2,440 $ 0.45 – 12.59 $ 3.80 Granted 705 5.91 - 8.09 6.84 Exercised (193) 1.05 - 5.10 2.39 Outstanding and exercisable at December 31, 2020 2,952 $ 0.45 – 12.59 $ 4.82 Granted 1,412 4.08 – 7.53 5.93 Exercised (11) 1.05 – 5.10 3.15 Forfeited (94) 7.40 – 8.09 7.79 Outstanding and exercisable at December 31, 2021 4,259 $ 0.45 – 12.59 $ 5.13 Summary of $USD Option Remaining Life Number Outstanding and Exercisable at Weighted Average Strike Price Weighted Average December 31, 2021 December 31, 2021 Remaining Life (in thousands) US Dollars (years) 4,259 5.13 7.00 Stock compensation expense for the fiscal years ended December 31, 2021 and 2020 was $4.0 million and $2.9 million, respectively. These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted and or vested during the fiscal years ended December 31, 2021 and 2020 was $5.93 and $6.84, respectively. The intrinsic value (being the difference between the share price at December 31, 2021 and exercise price) of stock options exercisable at December 31, 2021 was $0.30 million. The intrinsic value of options exercised during the fiscal year ended December 31, 2021 was $0.06 million. Of the 658 options issued in December 2021, 140 have standard vesting. There were 68 options awarded to various contractors. These 68 options were fully vested on the grant date of the award. There were 450 options awarded to our CEO, CFO and CCO. These options are performance-based and will vest, only upon FDA approval of our NDA. That FDA approval must occur in calendar year 2022 and the executives must still be employed by the Company. Currently, the Company has not recognized any expense associated with these performance-based awards. We will evaluate the probability of NDA approval at each balance sheet date and revise our expense extimate accordingly. The fair value of all options vested during the fiscal year ended December 31, 2021 was $0.5 million.The fair values of options granted in fiscal years ended December 31, 2021 and 2020 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions for all options with a ten-year expiration: Year Ended December 31, 2021 Year Ended December 31, 2020 Expected dividend 0 % 0 % Risk-free interest rate 1.41 - 1.62 % 0.63 - 1.90 % Expected volatility 122 % 136 - 148 % Expected life 10.0 years 10.0 years The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price. Restricted Share Units Activity The Plan allows for the issuance of restricted share units (“RSUs”). The following is a summary of RSU activity for the periods ended December 31, 2021 and 2020. All granted RSUs are denominated in U.S. dollars. Prior to June 2021, there was no activity involving RSUs. Of the 219 RSUs granted and outstanding million in RSU expense for the year ended December 31, 2021. Standard vesting of RSUs is over 1/3 1/24 Number of Restricted US Denominated RSU's Share Units (thousands) Outstanding at December 31, 2019 — Granted — Outstanding at December 31, 2020 — Granted 219 Outstanding at December 31, 2021 219 |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Measurements | |
Fair Value Measurements | 5. Fair Value Measurements The Company has adopted ASC 820 Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. Assets/Liabilities Measured at Fair Value on a Recurring Basis Fair Value Measurement at December 31, 2021 and December 31, 2020 (in thousands) Quoted Price in Active Market for Identical Significant Other Significant Instruments Observable Inputs Unobservable Inputs Level 1 Level 2 Level 3 Total 2021 2020 2021 2020 2021 2020 2021 2020 Assets Cash and cash equivalents 82 (1) 678 (1) 21,018 29,666 — — 21,100 30,344 Processa common shares — — 240 (2) 136 (2) — — 240 136 (1) The Company held approximately, $82,000 in cash as of December 31, 2021, of which approximately $34,000 was in Canadian funds (translated into U.S. dollars). As of December 31, 2020, the Company held approximately $678,000 , of which approximately $45,000 was in Canadian funds (translated into U.S. dollars). (2) The Company received 41,250 restricted common shares of Processa (PSCA). The share restriction will expire in three tranches: 50% , 25% and 25% at the 6, 9 and 12 month intervals, respectively from October 30, 2020. At October 30, 2020 PSCA shares were trading at $4.11 per share. The Company applied a 20% liquidity discount to the shares and will mark to market at each balance sheet date . |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 31, 2021 | |
Stockholders' Equity | |
Stockholders' Equity | 6. Stockholders’ Equity Authorized capital stock The Company’s authorized capital stock consists of an unlimited number of shares of no-par common shares. Warrants to Purchase Common Shares At December 31, 2021, the Company had 39,130 warrants outstanding to purchase common shares at an exercise price of $6.80. The following table summarized our warrant activity for the fiscal years ended December 31, 2021 and 2020. Number of Warrants Weighted (in thousands) Range Average Outstanding and exercisable at December 31, 2019 $ 39 $ 6.80 $ 6.80 Granted — — — Outstanding and exercisable at December 31, 2020 $ 39 $ 6.80 $ 6.80 Granted — — — Outstanding and exercisable at December 31, 2021 $ 39 $ 6.80 $ 6.80 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies | |
Commitments and Contingencies | 7. Commitments and Contingencies Oregon Health & Science University Agreement On February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including PEDMARK TM On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the OHSU Agreement, which expands Fennec's exclusive license to include the use of N-acetylcysteine as a standalone therapy and/or in combination with PEDMARK TM The term of the OHSU Agreement as amended by Amendment 1 expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. Sodium thiosulfate is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expired in Europe in 2021 and that expire in the United States in 2038. The OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the OHSU Agreement. Securities Class Action Suit Chapman et al. On September 2, 2020, a putative class action lawsuit, Chapman v. Fennec Pharmaceuticals Inc., was filed against us, our Chief Executive Officer, Rostislav Raykov, and our Chief Financial Officer, Robert Andrade, in the United States District Court for the Middle District of North Carolina. The complaint alleged that prior to our August 10, 2020 receipt of a CRL from the FDA concerning our NDA for PEDMARK TM TM TM Plaintiffs filed objections to the Magistrate Judge’s recommendation on January 24, 2022, and Defendants filed their response on February 3, 2022. The parties are currently awaiting a decision from the U.S. District Court Judge as to whether it will accept the Magistrate Judge’s recommendation. We believe that the suit is without merit and intend to defend it vigorously. We cannot predict the outcome of this suit. Failure by us to obtain a favorable resolution of the suit could have a material adverse effect on our business, results of operations and financial condition. We have not recorded a liability as of December 31, 2021, because we believe a potential loss is not probable or reasonably estimable given the preliminary nature of the proceedings. Jeffrey D. Fisher On February 9, 2022, plaintiff Jeffrey D. Fisher filed a putative federal securities class action against the Company and its CEO and CFO in the United States District Court for the Middle District of North Carolina, captioned Fisher v. Fennec Pharmaceuticals et al. , Case No. 1:22-cv-115 (M.D.N.C.). The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act by making materially false and misleading statements or omissions regarding the status of its PEDMARK TM manufacturing facility, the facility’s compliance with cGMP, and the impact its status and compliance would have on regulatory approval for PEDMARK TM in the period leading up to the Company’s November 29, 2021 receipt of a Complete Response Letter for a subsequent NDA for PEDMARK TM . The complaint seeks an unspecified amount of compensatory damages and other relief on behalf of persons who purchased the Company’s common stock from May 28, 2021 and November 26, 2021. We believe that the suit is without merit and intend to defend it vigorously. We cannot predict the outcome of this suit. Failure by us to obtain a favorable resolution of the suit could have a material adverse effect on our business, results of operations and financial condition. Hope Medical Enterprises, Inc. As discussed above under the heading “Business – Overview – Product Candidate,” On October 29, 2021, Hope Medical Enterprises, Inc. (“Hope”) filed two petitions for inter partes review (“IPR”) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO. In its petitions, Hope seeks to invalidate our U.S. Patent No. 10,596,190 (“US ‘190”), which is exclusively in-licensed from Oregon Health & Science University (“OHSU”) and relates to a method of using our PEDMARK™ product, and our U.S. Patent No. 10,792,363 (“US ’363”), which relates to an anhydrous form of STS, which is the active pharmaceutical ingredient in our PEDMARK™ product. US ‘190 was issued on March 24, 2020. US ‘363 was issued on October 6, 2020. We filed preliminary responses to the petitions in February 2022, and thereafter, the PTAB has three months to decide whether to institute IPR proceedings. If the PTAB institutes one or both reviews, the final written decision(s) will be due about one year after the PTAB’s decision to institute IPR proceedings, and following additional submissions by the parties. Any appeals of a PTAB decision would delay any final outcome. We plan to vigorously defend our intellectual property rights related to PEDMARK™. However, we are unable to predict the outcome of these petitions, and an invalidation of one or both of these patents may have a material adverse effect on our ability to protect our rights in PEDMARK™ beyond periods of marketing exclusivity for PEDMARK TM TM On January 11, 2022, our licensor OHSU filed a Request for Supplemental Examination of US ‘190 requesting the consideration by the USPTO of certain prior art references, including references cited by Hope in its Petition for IPR that are relevant to the granted claim of the patent. On January 28, 2022, the USPTO found that the cited references constitute a substantial new question of patentability and ordered an ex parte reexamination of the single US ‘190 claim of pursuant to 35 U.S.C. § 257. We are unable to predict the outcome of the ex parte TM TM Executive Severance In the event of his termination with us other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment equal to twelve months of salary (currently $458). In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment equal to six months of salary (currently $ 166). In the event of her termination with us other than for cause, we would have been obligated to pay Ms. Goel a one-time severance payment equal to six months of salary (currently $192). Ms. Goel tendered her resignation in January 2022. |
Term Loans
Term Loans | 12 Months Ended |
Dec. 31, 2021 | |
Term Loans | |
Term Loans | 8. Term Loans On June 24, 2021, the Company announced it had negotiated a second amendment to the Bridge Bank Loan and Security Agreement with Bridge Bank. This amendment provides Fennec with a $20,000 debt facility comprised of three term loans. Term Loan A consists of $5,000, which was funded upon closing. Term Loan B consists of $7,500 to be funded upon NDA approval of PEDMARKTM in the U.S. Term Loan C consists of $7,500 million to be funded upon the occurrence the Company achieving consolidated trailing six-month revenues of $11,000 on or before December 31, 2022. The interest-only period for the facility has the ability to be extended from 18 months to 24 months from the funding of Term Loan B, provided that Term Loan C is funded, and certain conditions are met. The Company intends to use the proceeds from the loans to provide working capital for commercial readiness activities prior to NDA approval as well as commercialization activities for PEDMARKTM, if approved by the FDA. On June 24, 2021, the Company drew $5,000 from Term Loan A. Term Loan A matures on July 1, 2025. Payments are for interest only through February 1, 2023. The Company shall make equal monthly payments of principal, together with applicable interest, following the interest only period until the maturity date. Interest shall accrue on the outstanding balance at a rate of 1% above prime as published by the Wall Street Journal on the first day of each month. The Company is obligated to maintain a cash balance greater or equal to three times its monthly cash burn as calculated on the last date of the immediately preceding month. Aggregate annual payments due on Term Loan A as of December 31, 2021 are as follows (in thousands): Years Ending December 31, Amount 2021 $ — 2022 — 2023 1,833 2024 2,000 2025 1,167 Total future payments 5,000 Less: unamortized debt discount (12) Total term loan, net of debt discount $ 4,988 In the event of default or change of control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable including the prepayment fee. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The Bridge Bank facility is secured by all of the Company’s assets, including all capital stock held by the Company. Debt issuance costs amounting to $55 securing access to Term Loans A, B and C were paid in cash to Bridge Bank on June 24, 2021. This amount was capitalized and is being amortized over the access period of the Term Loans. Upon drawing Term Loan A, the Company recorded a debt discount of $14, reducing the capitalized amount by the same amount. The debt discount is being amortized over the life of Term Loan A. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events | |
Subsequent Events | 9. Subsequent Events Officer Resignation On January 31, 2022, our Chief Commercial Officer, Ms. Goel resigned. Her resignation was voluntary and no severance was paid. The Company has added to its commercial team since the resignation of Ms. Goel. Bridge Bank Loan Facility On January 27, 2022, the Company entered into a third amendment to the Bridge Bank Loan and Security Agreement extending the outside date to receive NDA approval of PEDMARK TM Class Action Suit On February 9, 2022, plaintiff Jeffrey D. Fisher filed a putative federal securities class action against the Company and its CEO and CFO in the United States District Court for the Middle District of North Carolina, captioned Fisher v. Fennec Pharmaceuticals et al. , Case No. 1:22-cv-115 (M.D.N.C.). |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Taxes | |
Income Taxes | 10. Income Taxes The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows (in thousands except for percentage rates): Year Ended Year Ended December 31, December 31, 2021 2020 Domestic (loss)/gain $ (9,122) $ (8,784) Foreign loss (8,173) (9,283) Loss before income taxes (17,295) (18,067) Expected statutory rate (recovery) 26.50 % 26.50 % Expected provision for (recovery of) income tax (4,583) (4,788) Permanent differences 993 752 Change in valuation allowance 3,086 3,737 Effect of foreign exchange rate differences — — Effect of change in future enacted tax rates — — Tax credits and other adjustments — — Effect of tax rate changes and other 504 299 Provision for income taxes $ — $ — The Canadian statutory come tax rate of 26.0 percent is comprised of federal income tax at approximately 15.0 percent and provincial income tax at approximately 11.0 percent. The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2021 and December 31, 2020: December 31, December 31, 2021 2020 Future tax assets: SR&ED expenditures $ 2,086 $ 2,086 Income tax loss carryforwards 30,007 26,770 Non-refundable investment tax credits 700 1,083 Share issue costs 77 139 Accrued expenses — — Fixed and intangible assets 1,083 1,083 Reserves — — 33,953 31,161 Less: valuation allowance (33,927) (31,147) Net future tax assets $ 26 $ 14 Tax Cuts and Jobs Act On December 22, 2017, the then President of the United States signed into law an Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (commonly known as “the Tax Cuts and Jobs Act” (“TCJA”), which introduced a comprehensive set of tax reforms. The Tax Cuts and Jobs Act significantly revises U.S. tax law by, among other provisions, lowering the Company’s corporate tax rate from 34% to 21% and eliminating or reducing certain income tax deductions. In December 2017, in accordance with the SEC Staff Accounting Bulletin (“SAB”) 118–Income Tax Accounting Implications of the TCJA, the Company recorded tax effects on a provisional basis based on a reasonable estimate. The TCJA did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance and the Company does not have any offshore earnings from which to record the mandatory transition tax. During 2018, the Company completed its analysis under SAB 118 and no additional tax effects due to rate-remeasurement were required to be recorded. On March 27, 2020 the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its tax provision. There are no current income taxes owed, nor are any income taxes expected to be owed in the near term. At December 31, 2021 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry-forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below: Province/ Federal State SR&ED expenditures (no expiry) $ 7,872 $ — Income tax loss carryforwards (expiry date): 2021 26 — 2022 233 — 2023 1,588 — 2024 4,849 — 2025 6,143 6,169 2026 13,868 2,716 2027 8,136 4,219 2028 10,509 4,164 2029 8,185 2,116 2030 2,608 700 2031 3,378 789 2032 3,491 651 2033 1,789 655 2034 1,812 617 2035 1,804 941 2036 2,208 1,013 2037 4,641 1,638 2038 5,267 — 2039 5,848 — 2040 5,792 — 2041 5,602 No expiration 23,227 23,223 Investment tax credits (expiry date): 2022 379 2023 169 2024 189 2025 82 2026 86 2027 47 |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies | |
Basis of presentation | Basis of presentation The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation. |
Use of estimates | Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of stock-based compensation. Actual results could differ from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2021, the Company had $21.1 million in cash and money market accounts (2020- $30.3 million). Money market investments typically have minimal risks. While the Company has not experienced any loss or write-down of its money market investments, the amounts it holds in money market accounts are substantially above the $250,000 amount insured by the FDIC and may lose value. |
Financial instruments | Financial instruments Financial instruments recognized on the balance sheets at December 31, 2021 and December 31, 2020 consist of cash and cash equivalents, accounts payable, accrued liabilities and long term debt, the carrying values of which, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trading or speculative nature. |
Common shares and warrants | Common shares and warrants The Company has 0.04 million warrants with a weighted average strike price of $6.80 outstanding to purchase common shares that were denominated in United States dollars (“USD”). |
Revenue | Revenue The Company's revenue is generated through sales of intellectual property ("IP"). For periods when the Company has generated revenue, the revenue recognized under each of the Company’s arrangements during those periods is described below. The terms of these agreements may contain multiple promised goods or services or optional goods and services, including licenses to product candidates, referred to as exclusive licenses, as well as research and development activities to be performed by the Company on behalf of the collaboration partner related to the licensed product candidates. Revenue recognition Revenue is recognized when control of the promised goods or services are transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or providing services. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods or services, the Company considers the point at which the customer may benefit from the goods or services. For sale of IP, revenue is recognized upon grant or transfer of the IP, as the Company's IP is considered functional in nature. Performance obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may contain multiple performance obligations if a promise to transfer goods or services is separately identifiable from other promises in a contract and, therefore, is considered distinct. For contracts with multiple performance obligations, the Company determines the standalone selling price of each performance obligation and allocates the total transaction price using the relative selling price basis. The Company recognizes performance obligations based on their nature. Significant payment terms The Company's revenue arrangements include payments to the Company of one or more of the following: a non-refundable, upfront payment; milestone payments and royalties on commercial sales of IP product candidates, if any. To date, the Company has received upfront payments and several milestone payments but has not received any license or option fees or earned royalty revenue as a result of product sales. Under ASC 606, the Company estimates the amount of consideration to which it will be entitled in exchange for satisfying performance obligations. Based on the Company's current contracts, variable consideration primarily exists in the following forms: development and regulatory milestones, royalties and sales-based milestones. The Company utilizes the "most likely amount" variable consideration method for estimating development and regulatory milestone consideration to include in the transaction price. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company refers to this as the variable consideration constraint. Due to the uncertainty associated with the occurrence of the underlying events which would trigger development and regulatory milestone consideration under its revenue arrangements, with the exception of certain initial conditions precedent milestones, the Company has concluded the variable consideration associated with all development and regulatory milestones to be fully constrained as of the ASC 606 transition date and as of December 31, 2021, and therefore has not included such consideration in the transaction price for any of its revenue arrangements. The Company will reassess this conclusion at each subsequent reporting period and will only include amounts associated with regulatory or development milestones in the transaction price when, or if, the variable consideration is determined to be released from the constraint. In accordance with ASC 606, the Company is required to adjust the transaction price for the effects of the time value of money if the timing of payments agreed to by the parties to the contract, explicitly or implicitly, provides the Company or its customer with a significant benefit of financing the transfer of goods or services. The Company concluded that its licensing and collaboration arrangements do not contain a significant financing component because the payment structure of its agreements arise from reasons other than providing a significant benefit of financing. Contract assets The Company did not have a contract asset as of December 31, 2021 or 2020. Contract liabilities The Company did not have a contract liability as of December 31, 2021 or 2020. Revenue arrangements Elion In May 2016, Fennec sold its rights to the drug Eniluracil to Elion Oncology, LLC (“Elion”). The agreement called for $40,000 in cash and 5% royalties to be paid to Fennec for any income derived from the sale of Eniluracil. The agreement was for the sale, not license of Fennec’s rights in Eniluracil. In addition, the agreement did not call for any additional good or service beyond the transfer of Fennec’s rights in Eniluracil and related assets (e.g. "all information and know-how", documentation, etc.). In August 2020, Elion entered into a license agreement with Processa Pharmaceuticals, Inc. (“Processa”) for Eniluracil. The license agreement called for equity and cash upon satisfying the "Condition Precedent", along with development and regulatory milestone payments, Sales Milestone Payments, and Product Royalties. The grant of the license was conditioned upon the "Condition Precedent" which was defined as (i) Processa's closing of a public offering by October 30, 2020 in which Processa raised at least $15 million and (ii) Processa's shares being listed on NASDAQ. Upon satisfying the "Condition Precedent" Elion was entitled to receive $100,000 in cash and 825,000 in shares of Processa of which the Company is entitled to 5%. In January 2021, the Company received $5,000 in cash and 41,250 restricted shares of Processa common shares. The agreement between Elion and Processa entitles Elion to the payments outlined in the table below. Fennec would be eligible to receive 5% of the following based on future milestone events: Milestone Event Milestone Payment ($) 1st Year Anniversary of Effective Date 100 Restricted Shares 2nd Year Anniversary of Effective Date 100 Restricted Shares 1st Patient in Dose Confirmation Study 100 Restricted Shares NDA Submission 300 Restricted Shares 1st FDA Approval in US $ 5,000 2nd FDA Approval in US $ 3,000 1st Regulatory Approval Outside US $ 2,000 2nd Regulatory Approval Outside US $ 2,000 The Company notes that the above payments are conditioned upon the “Condition Precedent” and thus even the restricted shares that are due only upon the passage of time are in fact variable. However, once the “Condition Precedent” occurred only the passage of time must occur in order for the 1 st nd st nd th The arrangement with Elion contains consideration that is variable based on the customer’s achievement of certain development and regulatory milestones. The next milestone payment the Company may be entitled to receive is 5,000 restricted shares for 1 st The Company recognized $0.2 million in revenue associated with the aforementioned cash and shares it became entitled to for the year ended December 31, 2020. Due to the one year lockup provision on the Processa shares, the Company deemed it reasonable to apply a liquidity discount of 20% to the valuation of the shares associated with the achievement of the October 30, 2020 milestone. Shares associated with the one- and two-year anniversary milestones had a 30 and 40% liquidity discount applied to their fair market valuations. Recognizing the passage of time, the Company adjusted its liquidity discount to the original shares of Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the consolidated statement of operations. During the year ended December 31, 2021, the Company reported $25 in unrealized loss on the fair value of the underlying Processa shares. There is a total unrealized gain on the Processa shares of $75 since inception. |
Research and development costs and investment tax credits | Research and development costs and investment tax credits Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred. Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made, and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized. |
Income taxes | Income taxes The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December 31, 2021, we maintained a full valuation allowance against our deferred tax assets. The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. |
Foreign currency translation | Foreign currency translation The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations. |
Loss per share | Loss per share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number of common shares outstanding includes convertible debentures, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, warrants to purchase 0.04 million of our common shares and options to purchase 4.3 million of our common shares at December 31, 2021, were not included in earnings per share. Such options would have an antidilutive effect. In 2020, warrants to purchase 0.04 million of our common shares and options to purchase 3.0 million common shares were excluded from the computation of earnings per share as their inclusion would have been antidilutive. |
Recent accounting pronouncements | Recent accounting pronouncements In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848). In this ASU, the FASB refines the scope of Topic 848 to clarify that certain optional expedients and exceptions therein for contract modifications and hedge accounting apply to contracts that are affected by the discounting transition. Specifically, modifications related to reference rate reform would not be considered an event that requires reassessment of previous accounting conclusions. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The amendments in the ASU are effective immediately for all entities. Entities may choose to apply the amendments retrospectively as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or prospectively to new modifications from any date within an interim period that includes or is subsequent to January 7, 2021, up to the date that financial statements are available to be issued. The Company chose to apply amendments prospectively and concluded after evaluation that ASU 2021-01 has no significant effect on our consolidated financial statements. |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Significant Accounting Policies | |
Schedule of future milestone payments | Milestone Event Milestone Payment ($) 1st Year Anniversary of Effective Date 100 Restricted Shares 2nd Year Anniversary of Effective Date 100 Restricted Shares 1st Patient in Dose Confirmation Study 100 Restricted Shares NDA Submission 300 Restricted Shares 1st FDA Approval in US $ 5,000 2nd FDA Approval in US $ 3,000 1st Regulatory Approval Outside US $ 2,000 2nd Regulatory Approval Outside US $ 2,000 |
Loss per Share (Tables)
Loss per Share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Loss per Share | |
Schedule of Earnings Per Share, Basic and Diluted | Year Ended December 31, 2021 December 31, 2020 Numerator: Net loss $ (17,346) $ (18,109) Denominator: Weighted-average common shares, basic 26,006 23,704 Dilutive effect of stock options — — Dilutive effect of warrants — — Incremental dilutive shares — — Weighted-average common shares, diluted 26,006 23,704 Net loss per share, basic and diluted $ (0.67) $ (0.76) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Year Ended December 31, 2021 December 31, 2020 Options to purchase common shares 4,259 2,952 Warrants to purchase common shares 39 39 |
Stock options (Tables)
Stock options (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair values of options granted using weighted average assumptions | Year Ended December 31, 2021 Year Ended December 31, 2020 Expected dividend 0 % 0 % Risk-free interest rate 1.41 - 1.62 % 0.63 - 1.90 % Expected volatility 122 % 136 - 148 % Expected life 10.0 years 10.0 years |
Schedule of restricted share units activity | Number of Restricted US Denominated RSU's Share Units (thousands) Outstanding at December 31, 2019 — Granted — Outstanding at December 31, 2020 — Granted 219 Outstanding at December 31, 2021 219 |
Canadian Dollar [Member] | |
Schedule of Share-based Compensation, Stock Options, Activity | Summary of $CAD Option Activity Number of Weighted Share Prices Reported in $CAD Options Range Average (in thousands) Outstanding and exercisable at December 31, 2019 648 $ 2.43 $ 2.43 Exercised (648) 2.43 2.43 Outstanding and exercisable at December 31, 2020 — $ — $ — Outstanding and exercisable at December 31, 2021 — $ — $ — |
Currency, U.S. Dollar [Member] | |
Schedule of Share-based Compensation, Stock Options, Activity | Summary of $USD Option Activity Number of Options Weighted (in thousands) Range Average Outstanding and exercisable at December 31, 2019 2,440 $ 0.45 – 12.59 $ 3.80 Granted 705 5.91 - 8.09 6.84 Exercised (193) 1.05 - 5.10 2.39 Outstanding and exercisable at December 31, 2020 2,952 $ 0.45 – 12.59 $ 4.82 Granted 1,412 4.08 – 7.53 5.93 Exercised (11) 1.05 – 5.10 3.15 Forfeited (94) 7.40 – 8.09 7.79 Outstanding and exercisable at December 31, 2021 4,259 $ 0.45 – 12.59 $ 5.13 |
Schedule of options by exercise price range | Summary of $USD Option Remaining Life Number Outstanding and Exercisable at Weighted Average Strike Price Weighted Average December 31, 2021 December 31, 2021 Remaining Life (in thousands) US Dollars (years) 4,259 5.13 7.00 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Measurements | |
Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis | Assets/Liabilities Measured at Fair Value on a Recurring Basis Fair Value Measurement at December 31, 2021 and December 31, 2020 (in thousands) Quoted Price in Active Market for Identical Significant Other Significant Instruments Observable Inputs Unobservable Inputs Level 1 Level 2 Level 3 Total 2021 2020 2021 2020 2021 2020 2021 2020 Assets Cash and cash equivalents 82 (1) 678 (1) 21,018 29,666 — — 21,100 30,344 Processa common shares — — 240 (2) 136 (2) — — 240 136 (1) The Company held approximately, $82,000 in cash as of December 31, 2021, of which approximately $34,000 was in Canadian funds (translated into U.S. dollars). As of December 31, 2020, the Company held approximately $678,000 , of which approximately $45,000 was in Canadian funds (translated into U.S. dollars). (2) The Company received 41,250 restricted common shares of Processa (PSCA). The share restriction will expire in three tranches: 50% , 25% and 25% at the 6, 9 and 12 month intervals, respectively from October 30, 2020. At October 30, 2020 PSCA shares were trading at $4.11 per share. The Company applied a 20% liquidity discount to the shares and will mark to market at each balance sheet date . |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Stockholders' Equity | |
Schedule of Warrants Outstanding to Purchase Common Stock | Number of Warrants Weighted (in thousands) Range Average Outstanding and exercisable at December 31, 2019 $ 39 $ 6.80 $ 6.80 Granted — — — Outstanding and exercisable at December 31, 2020 $ 39 $ 6.80 $ 6.80 Granted — — — Outstanding and exercisable at December 31, 2021 $ 39 $ 6.80 $ 6.80 |
Term Loans (Tables)
Term Loans (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Term Loans | |
Schedule of aggregate annual payments | Aggregate annual payments due on Term Loan A as of December 31, 2021 are as follows (in thousands): Years Ending December 31, Amount 2021 $ — 2022 — 2023 1,833 2024 2,000 2025 1,167 Total future payments 5,000 Less: unamortized debt discount (12) Total term loan, net of debt discount $ 4,988 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Taxes | |
Schedule of reconciliation of the combined Canadian federal and provincial income tax rate with the effective tax rate | combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows (in thousands except for percentage rates): Year Ended Year Ended December 31, December 31, 2021 2020 Domestic (loss)/gain $ (9,122) $ (8,784) Foreign loss (8,173) (9,283) Loss before income taxes (17,295) (18,067) Expected statutory rate (recovery) 26.50 % 26.50 % Expected provision for (recovery of) income tax (4,583) (4,788) Permanent differences 993 752 Change in valuation allowance 3,086 3,737 Effect of foreign exchange rate differences — — Effect of change in future enacted tax rates — — Tax credits and other adjustments — — Effect of tax rate changes and other 504 299 Provision for income taxes $ — $ — |
Schedule of net future tax assets | The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2021 and December 31, 2020: December 31, December 31, 2021 2020 Future tax assets: SR&ED expenditures $ 2,086 $ 2,086 Income tax loss carryforwards 30,007 26,770 Non-refundable investment tax credits 700 1,083 Share issue costs 77 139 Accrued expenses — — Fixed and intangible assets 1,083 1,083 Reserves — — 33,953 31,161 Less: valuation allowance (33,927) (31,147) Net future tax assets $ 26 $ 14 |
Schedule of unclaimed amounts and their expiry dates | Province/ Federal State SR&ED expenditures (no expiry) $ 7,872 $ — Income tax loss carryforwards (expiry date): 2021 26 — 2022 233 — 2023 1,588 — 2024 4,849 — 2025 6,143 6,169 2026 13,868 2,716 2027 8,136 4,219 2028 10,509 4,164 2029 8,185 2,116 2030 2,608 700 2031 3,378 789 2032 3,491 651 2033 1,789 655 2034 1,812 617 2035 1,804 941 2036 2,208 1,013 2037 4,641 1,638 2038 5,267 — 2039 5,848 — 2040 5,792 — 2041 5,602 No expiration 23,227 23,223 Investment tax credits (expiry date): 2022 379 2023 169 2024 189 2025 82 2026 86 2027 47 |
Nature of Business and Liquid_2
Nature of Business and Liquidity - Additional Information (Details) | Jun. 24, 2021USD ($)loan | Jun. 25, 2020USD ($)loan | May 05, 2020USD ($)$ / sharesshares | Feb. 01, 2019USD ($)$ / sharesshares | Dec. 31, 2021USD ($)$ / shares | Dec. 31, 2020USD ($)$ / shares | Dec. 31, 2019$ / shares |
Going Concern [Line Items] | |||||||
Loss from operations | $ (17,223,000) | $ (17,885,000) | |||||
Accumulated deficit | (179,486,000) | (162,140,000) | |||||
Cash flows from operating activities | $ (14,222,000) | $ (15,595,000) | |||||
Issuance of securities (in shares) | shares | 4,800,000 | ||||||
Shares issued, exercise price | $ / shares | $ 6.25 | ||||||
Total gross proceeds from the offering | $ 34,100,000 | ||||||
Net proceeds from public offering | $ 32,189,000 | ||||||
Warrants exercise price | $ / shares | $ 6.80 | $ 6.80 | $ 6.80 | ||||
Bridge Bank Term Loan | |||||||
Going Concern [Line Items] | |||||||
Debt amount | $ 20,000,000 | ||||||
Number of loans | loan | 3 | 2 | |||||
Revenue achievement trailing period | 6 months | ||||||
Revenue threshold amount for loan to be funded | $ 11,000,000 | ||||||
Bridge Bank Term Loan | Minimum | |||||||
Going Concern [Line Items] | |||||||
Interest only period | 18 months | ||||||
Bridge Bank Term Loan | Maximum | |||||||
Going Concern [Line Items] | |||||||
Interest only period | 24 months | ||||||
Term Loan A | |||||||
Going Concern [Line Items] | |||||||
Line of credit facility, borrowing capacity | $ 12,500,000 | ||||||
Debt amount | $ 5,000,000 | ||||||
Term Loan B | |||||||
Going Concern [Line Items] | |||||||
Debt amount | 7,500,000 | ||||||
Term Loan C | |||||||
Going Concern [Line Items] | |||||||
Debt amount | $ 7,500,000 | ||||||
Revenue achievement trailing period | 6 months | ||||||
Revenue threshold amount for loan to be funded | $ 11,000,000 | ||||||
Overallotment Option | |||||||
Going Concern [Line Items] | |||||||
Issuance of securities (in shares) | shares | 660,204 | ||||||
Bridge Bank | |||||||
Going Concern [Line Items] | |||||||
Line of credit facility, borrowing capacity | $ 18,000,000 | ||||||
Bridge Bank | Loan And Security Agreement | Term Loan A | |||||||
Going Concern [Line Items] | |||||||
Shares issued, exercise price | $ / shares | $ 6.80 | ||||||
Line of credit facility, borrowing capacity | $ 12,500,000 | ||||||
Shares, issued | shares | 39,130,000 | ||||||
Warrants exercise term | 10 years | ||||||
Basis above prime rate | 3.25% | ||||||
Debt instrument, interest rate, stated percentage | 1.00% | ||||||
Bridge Bank | Minimum | Term Loan A | |||||||
Going Concern [Line Items] | |||||||
Line Of Credit Facility, Interest Only Period | 18 months | ||||||
Bridge Bank | Term Loan A | |||||||
Going Concern [Line Items] | |||||||
Line Of Credit Facility, Interest Only Period | 24 months | ||||||
Bridge Bank | Term Loan A | Minimum | |||||||
Going Concern [Line Items] | |||||||
Line Of Credit Facility, Interest Only Period | 18 months | ||||||
Bridge Bank | Term Loan B | |||||||
Going Concern [Line Items] | |||||||
Line of credit facility, borrowing capacity | $ 5,500,000 | ||||||
Line of Credit Facility, Commitment Fee Percentage | 2.13% | ||||||
Bridge Bank | Term Loan B | Warrants | |||||||
Going Concern [Line Items] | |||||||
Line of Credit Facility, Commitment Fee Percentage | 3.25% |
Significant Accounting Polici_4
Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
May 31, 2016USD ($) | Dec. 31, 2021USD ($)$ / sharesshares | Dec. 31, 2021USD ($)$ / sharesshares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2020CAD ($)shares | Dec. 31, 2019USD ($)$ / sharesshares | Dec. 31, 2019CAD ($)shares | |
Summary Of Significant Accounting Policies [Line Items] | |||||||
Money market investments | $ 21,100 | $ 21,100 | $ 30,300 | ||||
Cash | $ 82,000 | $ 34,000 | $ 678,000 | $ 45,000 | |||
FDIC insured amount | $ 250,000 | $ 250,000 | |||||
Warrants exercise price | $ / shares | $ 6.80 | $ 6.80 | $ 6.80 | $ 6.80 | |||
Class of Warrant or Right, Outstanding | shares | 39,130 | 39,130 | 39,000 | 39,000 | 39,000 | 39,000 | |
Percentage of royalties | 5.00% | ||||||
Debt Securities, Unrealized Gain (Loss) | $ 75 | $ (25) | $ 100 | ||||
Options | |||||||
Summary Of Significant Accounting Policies [Line Items] | |||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 4,300,000 | 3,000,000 | |||||
Eniluracil | Elion | |||||||
Summary Of Significant Accounting Policies [Line Items] | |||||||
Cash proceeds from sale of Eniluracil | $ 40,000 | ||||||
Percentage of royalties | 5.00% |
Significant Accounting Polici_5
Significant Accounting Policies (Details) - USD ($) $ in Thousands | Oct. 30, 2020 | Jan. 31, 2021 | Aug. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Percentage of royalties | 5.00% | ||||
Revenues | $ 170 | ||||
1st Year Anniversary of Effective Date | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 100,000 | ||||
2nd Year Anniversary of Effective Date | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 100,000 | ||||
1st Patient in Dose Confirmation Study | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 100,000 | ||||
NDA Submission | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 300,000 | ||||
1st FDA Approval in US | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Milestone payment | $ 5,000 | ||||
2nd FDA Approval in US | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Milestone payment | 3,000 | ||||
1st Regulatory Approval Outside US | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Milestone payment | 2,000 | ||||
2nd Regulatory Approval Outside US | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Milestone payment | $ 2,000 | ||||
Elion | Restricted shares | 1st Patient in Dose Confirmation Study | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 5,000 | ||||
Elion | Restricted shares | NDA Submission | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 15,000 | ||||
Processa Pharmaceuticals, Inc | License agreement | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Upfront payment | $ 5,000 | ||||
Processa Pharmaceuticals, Inc | License agreement | Restricted shares | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Shares to be issued under agreement | 41,250 | 41,250,000 | |||
Revenues | $ 200 | ||||
Lockup period | 1 year | ||||
Liquidity discount (as a percent) | 20.00% | 20.00% | |||
Adjusted liquidity discount (as a percent) | 0.00% | ||||
Processa Pharmaceuticals, Inc | License agreement | Restricted shares | 1st Year Anniversary of Effective Date | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Liquidity discount (as a percent) | 30.00% | ||||
Adjusted liquidity discount (as a percent) | 20.00% | ||||
Processa Pharmaceuticals, Inc | License agreement | Restricted shares | 2nd Year Anniversary of Effective Date | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Liquidity discount (as a percent) | 40.00% | ||||
Adjusted liquidity discount (as a percent) | 25.00% | ||||
Processa Pharmaceuticals, Inc | Elion | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Minimum proceeds from public offering | $ 15,000 | ||||
Upfront payment | $ 100,000 | ||||
Shares to be issued under agreement | 825,000,000 |
Loss per Share - Computation of
Loss per Share - Computation of Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Numerator: | ||
Net loss | $ (17,346) | $ (18,109) |
Denominator: | ||
Weighted-average common shares, basic | 26,006 | 23,704 |
Weighted-average common shares, dilutive | 26,006 | 23,704 |
Net loss per share, basic and diluted | $ (0.67) | $ (0.76) |
Loss per Share - Outstanding Op
Loss per Share - Outstanding Options and Warrants (Details) - shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 4,259 | 2,952 |
Warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 39 | 39 |
Stock Options - Options Granted
Stock Options - Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars (Details) shares in Thousands | 12 Months Ended | |||
Dec. 31, 2021$ / sharesshares | Dec. 31, 2021$ / sharesshares | Dec. 31, 2020$ / sharesshares | Dec. 31, 2020$ / sharesshares | |
Outstanding and Exercisable Range | $ 2.43 | |||
Exercised Range | $ 2.43 | |||
Options | ||||
Vesting period | 3 years | 3 years | ||
Expiration term | 10 years | 10 years | ||
Canadian Dollar [Member] | ||||
Number of Options Outstanding and Exercisable at Beginning | shares | 648 | 648 | ||
Number of Options Exercised | shares | (648) | (648) | ||
Number of Options Outstanding and Exercisable at Ending | shares | 0 | 0 | ||
Outstanding and Exercisable Range | $ 2.43 | |||
Outstanding and Exercisable Range | $ 0 | |||
Weighted- Average Exercised | $ 2.43 | |||
Weighted Average Exercise Price Outstanding and Exercisable at Ending | $ 0 | |||
Currency, U.S. Dollar [Member] | ||||
Number of Options Outstanding and Exercisable at Beginning | shares | 2,952 | 2,952 | 2,440 | 2,440 |
Number of Options Granted | shares | 1,412 | 1,412 | 705 | 705 |
Number of Options Exercised | shares | (11) | (11) | (193) | (193) |
Number of Options Forfeited | shares | (94) | (94) | ||
Number of Options Outstanding and Exercisable at Ending | shares | 4,259 | 4,259 | 2,952 | 2,952 |
Weighted Average Exercise Price Outstanding and Exercisable at Beginning | $ 4.82 | $ 3.80 | ||
Weighted- Average Granted | 5.93 | 6.84 | ||
Weighted- Average Exercised | 3.15 | 2.39 | ||
Weighted- Average Forfeited or expired | 7.79 | |||
Weighted Average Exercise Price Outstanding and Exercisable at Ending | 5.13 | 4.82 | ||
Currency, U.S. Dollar [Member] | Minimum | ||||
Outstanding and Exercisable Range | 0.45 | 0.45 | ||
Granted Range | 4.08 | 5.91 | ||
Exercised Range | 1.05 | 1.05 | ||
Forfeited or expired Range | 7.40 | |||
Outstanding and Exercisable Range | 0.45 | 0.45 | ||
Currency, U.S. Dollar [Member] | Maximum | ||||
Outstanding and Exercisable Range | 12.59 | 12.59 | ||
Granted Range | 7.53 | 8.09 | ||
Exercised Range | 5.10 | 5.10 | ||
Forfeited or expired Range | 8.09 | |||
Outstanding and Exercisable Range | $ 12.59 | $ 12.59 |
Stock Options - Price In US Dol
Stock Options - Price In US Dollars (Details) - Currency, U.S. Dollar [Member] - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Number Outstanding and Exercisable | 4,259 | 2,952 | 2,440 |
Weighted Average Strike Price in US Dollars | $ 5.13 | ||
Weighted Average Remaining Life (years) | 7 years |
Stock Options - Options Were Gr
Stock Options - Options Were Granted Based On The Black Scholes Option Pricing Model (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Expected dividend | 0.00% | 0.00% |
Expected volatility | 122.00% | |
Expected life | 10 years | 10 years |
Minimum | ||
Risk-free interest rate | 1.41% | 0.63% |
Expected volatility | 136.00% | |
Maximum | ||
Risk-free interest rate | 1.62% | 1.90% |
Expected volatility | 148.00% |
Stock options - Restricted Shar
Stock options - Restricted Share Units Activity (Details) - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vested | 34 | |
RSU expense recognized | $ 0.1 | |
Vesting on the first anniversary date of the grant | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vested | 110 | |
Chief Financial Officer And Chief Compliance officer [Member] | ||
US Denominated RSU's | ||
Granted | 75 | |
Equity Incentive Plan | US Denominated RSU's | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vested | 0 | |
US Denominated RSU's | ||
Outstanding at beginning of period | 0 | 0 |
Granted | 219 | 0 |
Outstanding at end of period | 219 | 0 |
Equity Incentive Plan | US Denominated RSU's | Vesting on the first anniversary date of the grant | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 3 years | |
Vesting percentage | 33.00% | |
US Denominated RSU's | ||
Granted | 34 | |
Equity Incentive Plan | US Denominated RSU's | Vesting on the last day of each subsequent month | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting percentage | 4.17% |
Stock options - Additional Info
Stock options - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | Jun. 24, 2010 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $ 300 | $ 300 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | 60 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 500 | |||
Expiration period | 10 years | |||
Number of Options | 658 | |||
Number of options vested | 140 | |||
Contractors | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of options vested | 68 | |||
CEO, CFO and CCO | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of options vested | 450 | |||
General and Administrative Expense [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Allocated Share-based Compensation Expense | $ 4,000 | $ 2,900 | ||
Plan Maximum Amendment [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares issuable under Stock Option Plan | 6,500,000 | |||
Stock Option [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares issuable under Stock Option Plan | 6,700,000 | |||
Percentage Of Total Number Of Share Issued and Outstanding | 25.00% | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 5.93 | $ 6.84 |
Fair Value Measurements - Asset
Fair Value Measurements - Assets/Liabilities Measured at Fair Value (Details) - USD ($) $ / shares in Units, $ in Thousands | Oct. 30, 2020 | Jan. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Cash and cash equivalents | $ 21,100 | $ 30,344 | ||
Quoted Price in Active Markets for Identical Instruments Level 1 [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Cash and cash equivalents | 82 | 678 | ||
Significant Other Observable Inputs Level 2 [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Cash and cash equivalents | 21,018 | 29,666 | ||
Significant Unobservable Inputs Level 3 [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Cash and cash equivalents | 0 | 0 | ||
Processa Pharmaceuticals, Inc | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Processa common shares | 240 | 136 | ||
Processa Pharmaceuticals, Inc | Significant Other Observable Inputs Level 2 [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Processa common shares | 240 | 136 | ||
Processa Pharmaceuticals, Inc | Significant Unobservable Inputs Level 3 [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Processa common shares | $ 0 | $ 0 | ||
License agreement | Processa Pharmaceuticals, Inc | Restricted shares | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Shares to be issued under agreement | 41,250 | 41,250,000 | ||
Share price | $ 4.11 | |||
Liquidity discount (as a percent) | 20.00% | 20.00% | ||
License agreement | Processa Pharmaceuticals, Inc | Restricted shares | 6 month interval | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Expiration of share restriction | 50.00% | |||
License agreement | Processa Pharmaceuticals, Inc | Restricted shares | 9 month interval | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Expiration of share restriction | 25.00% | |||
License agreement | Processa Pharmaceuticals, Inc | Restricted shares | 12 month interval | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Expiration of share restriction | 25.00% |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) $ in Thousands, $ in Thousands | Dec. 31, 2020USD ($) | Dec. 31, 2020CAD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2019CAD ($) |
Fair Value Measurements | ||||
Cash | $ 82,000 | $ 34,000 | $ 678,000 | $ 45,000 |
Stockholders' Equity - Authoriz
Stockholders' Equity - Authorized capital stock (Details) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Stockholders' Equity | ||
Common stock, no par value | $ 0 | $ 0 |
Stockholders' Equity - Warrants
Stockholders' Equity - Warrants to Purchase Common Stock (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Class of Warrant or Right [Line Items] | ||
Outstanding and exercisable at the beginning | 39,000 | 39,000 |
Granted | 0 | 0 |
Outstanding and exercisable at the end | 39,130 | 39,000 |
Weighted-Average Outstanding, beginning | $ 6.80 | $ 6.80 |
Granted (in dollars per share) | 0 | 0 |
Weighted-Average Outstanding, end | 6.80 | 6.80 |
Minimum | ||
Class of Warrant or Right [Line Items] | ||
Exercised | 6.80 | |
Weighted Average [Member] | ||
Class of Warrant or Right [Line Items] | ||
Weighted-Average Outstanding, beginning | 6.80 | 6.80 |
Granted (in dollars per share) | 0 | 0 |
Weighted-Average Outstanding, end | $ 6.80 | $ 6.80 |
Commitments and Contingencies (
Commitments and Contingencies (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Rostislav Raykov [Member] | |
Severance Costs Payable In Case Of Termination Other Than For Cause | $ 458 |
Robert Andrade [Member] | |
Severance Costs Payable In Case Of Termination Other Than For Cause | 166 |
Goel [Member] | |
Severance Costs Payable In Case Of Termination Other Than For Cause | $ 192 |
Term Loans (Details)
Term Loans (Details) $ in Thousands | Jun. 24, 2021USD ($)loan | Dec. 31, 2021USD ($) | Jun. 25, 2020loan |
Term Loans. | |||
Amount drawn | $ 5,000 | ||
Bridge Bank Term Loan | |||
Term Loans. | |||
Debt amount | $ 20,000 | ||
Number of loans | loan | 3 | 2 | |
Revenue achievement trailing period | 6 months | ||
Revenue threshold amount for loan to be funded | $ 11,000 | ||
Bridge Bank Term Loan | Minimum | |||
Term Loans. | |||
Interest only period | 18 months | ||
Bridge Bank Term Loan | Maximum | |||
Term Loans. | |||
Interest only period | 24 months | ||
Term Loan A | |||
Term Loans. | |||
Debt amount | $ 5,000 | ||
Amount drawn | $ 5,000 | ||
Cash balance to be maintained multiplier | 3 | ||
Term Loan A | Prime Rate | |||
Term Loans. | |||
Basis above prime rate | 1.00% | ||
Term Loan B | |||
Term Loans. | |||
Debt amount | $ 7,500 | ||
Term Loan C | |||
Term Loans. | |||
Debt amount | $ 7,500 | ||
Revenue achievement trailing period | 6 months | ||
Revenue threshold amount for loan to be funded | $ 11,000 |
Term Loans - Aggregate annual p
Term Loans - Aggregate annual payments due on Term Loan (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Jun. 24, 2021 |
Aggregate annual payments due on Term Loan | ||
Total future payments | $ 5,000 | |
Less: unamortized debt discount | (12) | |
Term Loan A | ||
Aggregate annual payments due on Term Loan | ||
2023 | 1,833 | |
2024 | 2,000 | |
2025 | 1,167 | |
Total future payments | 5,000 | |
Less: unamortized debt discount | (12) | $ (14) |
Total term Loan | $ 4,988 |
Term Loans - Additional Informa
Term Loans - Additional Information (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Jun. 24, 2021 |
Term Loans. | ||
Debt discount | $ 12 | |
Bridge Bank Term Loan | ||
Term Loans. | ||
Debt issuance costs | $ 55 | |
Term Loan A | ||
Term Loans. | ||
Debt discount | $ 12 | $ 14 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Details) $ in Thousands | Jan. 31, 2022USD ($) |
Subsequent Event | |
Voluntary resignation severance cost | $ 0 |
Income Taxes - Canadian federal
Income Taxes - Canadian federal and provincial income tax rate (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | |
Income Taxes | |||
Domestic (loss)/gain | $ (9,122) | $ (8,784) | |
Foreign loss | (8,173) | (9,283) | |
Loss before income taxes | $ (17,295) | $ (18,067) | |
Expected statutory rate (recovery) | 26.50% | 26.50% | 34.00% |
Expected provision for (recovery of) income tax | $ (4,583) | $ (4,788) | |
Permanent differences | 993 | 752 | |
Change in valuation allowance | 3,086 | 3,737 | |
Effect of foreign exchange rate differences | 0 | 0 | |
Effect of change in future enacted tax rates | 0 | 0 | |
Tax credits and other adjustments | 0 | 0 | |
Effect of tax rate changes and other | 504 | 299 | |
Provision for income taxes | $ 0 | $ 0 |
Income Taxes- Future Income Tax
Income Taxes- Future Income Taxes (Recovery) (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | $ 33,953 | $ 31,161 |
Less: valuation allowance | (33,927) | (31,147) |
Net future tax assets | 26 | 14 |
SR&ED expenditures [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | 2,086 | 2,086 |
Non refundable Investment Tax Credits [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | 700 | 1,083 |
Share Issue Costs [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | 77 | 139 |
Accrued Expenses [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | 0 | 0 |
Income Tax Loss Carry forwards [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | 30,007 | 26,770 |
Fixed and intangible assets [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | 1,083 | 1,083 |
Reserves [Member] | ||
Income Taxes Future Recovery Disclosure [Line Items] | ||
Future tax assets gross | $ 0 | $ 0 |
Income Taxes - Income Tax Loss
Income Taxes - Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Province State [Member] | |
Income Tax [Line Items] | |
SR & ED expenditures (no expiry) | $ 0 |
Province State [Member] | Year 2021 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | Year 2022 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | Year 2023 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | Year 2024 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | Year 2025 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 6,169 |
Province State [Member] | Year 2026 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 2,716 |
Province State [Member] | Year 2027 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 4,219 |
Province State [Member] | Year 2028 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 4,164 |
Province State [Member] | Year 2029 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 2,116 |
Province State [Member] | Year 2030 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 700 |
Province State [Member] | Year 2031 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 789 |
Province State [Member] | Year 2032 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 651 |
Province State [Member] | Year 2033 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 655 |
Province State [Member] | Year 2034 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 617 |
Province State [Member] | Year 2035 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 941 |
Province State [Member] | Year 2036 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 1,013 |
Province State [Member] | Year 2037 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 1,638 |
Province State [Member] | Year 2038 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | Year 2039 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | Year 2040 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 0 |
Province State [Member] | No expiration | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 23,223 |
Federal [Member] | |
Income Tax [Line Items] | |
SR & ED expenditures (no expiry) | 7,872 |
Federal [Member] | Year 2021 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 26 |
Federal [Member] | Year 2022 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 233 |
Investment tax credits (expiry date) | 379 |
Federal [Member] | Year 2023 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 1,588 |
Investment tax credits (expiry date) | 169 |
Federal [Member] | Year 2024 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 4,849 |
Investment tax credits (expiry date) | 189 |
Federal [Member] | Year 2025 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 6,143 |
Investment tax credits (expiry date) | 82 |
Federal [Member] | Year 2026 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 13,868 |
Investment tax credits (expiry date) | 86 |
Federal [Member] | Year 2027 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 8,136 |
Investment tax credits (expiry date) | 47 |
Federal [Member] | Year 2028 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 10,509 |
Federal [Member] | Year 2029 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 8,185 |
Federal [Member] | Year 2030 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 2,608 |
Federal [Member] | Year 2031 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 3,378 |
Federal [Member] | Year 2032 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 3,491 |
Federal [Member] | Year 2033 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 1,789 |
Federal [Member] | Year 2034 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 1,812 |
Federal [Member] | Year 2035 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 1,804 |
Federal [Member] | Year 2036 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 2,208 |
Federal [Member] | Year 2037 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 4,641 |
Federal [Member] | Year 2038 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 5,267 |
Federal [Member] | Year 2039 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 5,848 |
Federal [Member] | Year 2040 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 5,792 |
Federal [Member] | Year 2041 [Member] | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | 5,602 |
Federal [Member] | No expiration | |
Income Tax [Line Items] | |
Income tax loss carryforwards (expiry date) | $ 23,227 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) | 12 Months Ended | 24 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2017 | Dec. 31, 2021 | |
Income Taxes Disclosure Additional Information [Line Items] | ||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 26.50% | 26.50% | 34.00% | |
Canadian Statutory Income Tax [Member] | ||||
Income Taxes Disclosure Additional Information [Line Items] | ||||
Income tax Rate | 26.00% | |||
Federal Income Tax [Member] | ||||
Income Taxes Disclosure Additional Information [Line Items] | ||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | |||
Income tax Rate | 15.00% | 15.00% | ||
Provincial Income Tax [Member] | ||||
Income Taxes Disclosure Additional Information [Line Items] | ||||
Income tax Rate | 11.00% | 11.00% |